USA – Vasa Therapeutics, an Encinitas, CA-based preclinical stage biopharmaceutical company developing novel therapies for cardiovascular aging, closed a Seed funding of $6M supplemented by $2.3M non-dilutive grant funding.
The round was led by Orphinic Scientific and included participation from private investments funds NuFund Venture Group, SeedFolio, and others. Orphinic’s chairman of supervisory board, Prof. Jarosław Leszczyszyn, will join Vasa’s board of directors.The company intends to use the funds to advance novel therapies for cardiovascular diseases. Led by CEO Artur Plonowski, MD, PhD, CEO, Vasa is a biopharmaceutical company developing therapeutics that target pathophysiology of cardiovascular aging: 03/01/2024
